Moderna (BRSE:0QF) - Stock Price, News & Analysis

0QF Stock Overview

0QF fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 60% below our estimate of its fair value

Risk Analysis

Earnings are forecast to decline by an average of 15.5% per year for the next 3 years

High level of non-cash earnings

Shares are highly illiquid

Profit margins (43.4%) are lower than last year (66.1%)

Moderna, Inc. Competitors

Basilea Pharmaceutica

SWX:BSLN

CHF495.1m

Lonza Group

SWX:LONN

CHF38.0b

Roche Holding

SWX:ROG

CHF185.3b

Novartis

SWX:NOVN

CHF181.5b

Price History & Performance

Summary of all time highs, changes and price drops for Moderna
Historical stock prices
Current Share Price	US$184.33
52 Week High	US$0
52 Week Low	US$0
Beta	1.7
1 Month Change	0%
3 Month Change	10.98%
1 Year Change	40.56%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	52.51%

Recent updates

Shareholder Returns

	0QF	CH Biotechs	CH Market
7D	0%	-2.6%	2.0%
1Y	40.6%	8.7%	-2.8%

Return vs Industry: 0QF exceeded the Swiss Biotechs industry which returned -24.8% over the past year.

Return vs Market: 0QF exceeded the Swiss Market which returned -0.9% over the past year.

Price Volatility

Is 0QF's price volatile compared to industry and market?
0QF volatility
0QF Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.5%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.3%
10% least volatile stocks in CH Market	1.9%

Stable Share Price: 0QF has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0QF's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	3,900	Stephane Bancel	www.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
0QF fundamental statistics
Market cap	CHF49.23b
Earnings (TTM)	CHF7.70b
Revenue (TTM)	CHF17.75b

6.4x

P/E Ratio

2.8x

P/S Ratio

Is 0QF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QF income statement (TTM)
Revenue	US$19.26b
Cost of Revenue	US$8.71b
Gross Profit	US$10.55b
Other Expenses	US$2.19b
Earnings	US$8.36b

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	21.64
Gross Margin	54.78%
Net Profit Margin	43.41%
Debt/Equity Ratio	0%

How did 0QF perform over the long term?

See historical performance and comparison

0QF Stock Overview

Rewards

Risk Analysis

Moderna, Inc. Competitors

SWX:BSLN

CHF495.1m

SWX:LONN

CHF38.0b

SWX:ROG

CHF185.3b

SWX:NOVN

CHF181.5b

Price History & Performance

Recent News & Updates

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Investor sentiment improved over the past week

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Moderna, Inc. Announces Executive Changes

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Third quarter 2022 earnings released: EPS: US$2.67 (vs US$8.25 in 3Q 2021)

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Investor sentiment improved over the past week

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union

Moderna, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Moderna, Inc. Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Investor sentiment improved over the past week

Moderna, Inc. Announces Management Changes

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EMA Committee for Medicinal Products for Human Use (Chmp) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Moderna, Inc. Announces Swissmedic Authorizes its Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Moderna, Inc. Announces Executive Changes

Moderna, Inc. Announces Medicines and Healthcare Products Regulatory Agency Authorizes Omicron-Containing Bivalent Booster in the Uk

Moderna, Inc. Fires Jorge Gomez as CFO

Moderna, Inc. Appoints Arpa Garay as Chief Commercial Officer, Effective May 31, 2022

Moderna, Inc. to Report Q1, 2022 Results on May 04, 2022

Shareholder Returns

Price Volatility

About the Company